ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
13.33
-0.15 (-1.11%)
At close: Aug 6, 2026, 4:00 PM EDT
13.75
+0.42 (3.15%)
After-hours: Aug 6, 2026, 6:45 PM EDT
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
119.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cue Biopharma | 32.73M |
| Seer, Inc. | 15.17M |
| NRx Pharmaceuticals | 2.29M |
| Spruce Biosciences | 697.00K |
| Genelux | 8.00K |
PMN News
- 3 days ago - ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - GlobeNewsWire
- 8 days ago - ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim - TheFly
- 9 days ago - ProMIS Neurosciences price target raised to $33 from $20 at Chardan - TheFly
- 9 days ago - ProMIS Neurosciences Transcript: Study result - Transcripts
- 9 days ago - ProMIS Neurosciences Slides: Study result - Filings
- 9 days ago - ProMIS Neurosciences Press release: Study result - Filings
- 9 days ago - ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim - TheFly
- 9 days ago - ProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial - TheFly